Agoracom Blog Home

Posts Tagged ‘CBD’

« Older Entries
Newer Entries »

Empower Clinics $CBDT.ca Expands COVID-19 Testing Programs by Commencing RT-PCR Testing $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 6:56 AM on Thursday, September 10th, 2020
  • Commenced COVID-19 reverse transcription polymerase chain reaction (RT-PCR), testing through its Sun Valley Health operations in Arizona, using RT-PCR test kits and laboratory test processing by Kai Medical Laboratory in Dallas, TX., the recently announced proposed acquisition target by Empower
  • programs are part of a “Back to Work” and “Back to School” initiative supported by a variety of outbound marketing campaigns including new Facebook ads, text message & email campaigns and outbound call-center campaigns targeting businesses, universities & colleges, sports teams or organizations where effective social distancing could be difficult.

VANCOUVER BC / September 10, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) (“Empower” or the “Company“) today announces it has commenced COVID-19 reverse transcription polymerase chain reaction (RT-PCR), testing through its Sun Valley Health operations in Arizona, using RT-PCR test kits and laboratory test processing by Kai Medical Laboratory in Dallas, TX., the recently announced proposed acquisition target by Empower.

The programs are part of a “Back to Work” and “Back to School” initiative supported by a variety of outbound marketing campaigns including new Facebook ads, text message & email campaigns and outbound call-center campaigns targeting businesses, universities & colleges, sports teams or organizations where effective social distancing could be difficult.

RT-PCR Testing can be booked via: https://www.sunvalleyhealth.com/covid-19-test-book-now/

Currently Kai Medical Laboratory has the capacity to complete in excess of 2,000 RT-PCR tests in one eight-hour shift by utilizing its Thermo Fisher QuantStudio 12k Flex testing machine.

“Launching our RT-PCR testing programs utilizing the capability of Kai Medical Labs gives us the ability to access massive testing volume not only in Arizona, but nationwide in the U.S.” said Steven McAuley, Empower’s Chairman & CEO. “Our team at Sun Valley Health has created numerous strategic marketing campaigns to drive awareness and testing volume, leveraging our supply chain improvements with increased profit margins.”

Many schools and universities are now requiring students and teachers to provide RT-PCR testing results prior to returning to campus. Our nasal or throat swab RT-PCR testing program allow students and teachers to quickly be tested and receive results from a Clinical Laboratory Improvement Amendments (CLIA), accredited laboratory in only 24 – 48 hours.

Businesses need a stable workforce, and must be quick to isolate employees with any symptoms. Our RT-PCR testing allows employees to be tested quickly and receive results within 24 – 48 hours, giving the employee and the employer the opportunity to activate non-contagious employees and safely return to work!

Travelers are also discovering demands to get a RT-PCR test and provide the result upon check-in at the airport. The reports are required to be no more than 3 days old. Our testing program provides accurate results within 24-48 hours, giving the patient a document that can make the difference in being able to travel.

https://www.cdc.gov/coronavirus/2019-ncov/community/schools-childcare/k-12-testing.html
https://www.wsj.com/articles/universities-plan-robust-covid-19-testing-for-returning-students-11594812937

An RT-PCR assay is a viral molecular test to detect active infection directly in a patient’s RNA genetic sequence. An RT-PCR swab test is considered the gold-standard for testing & diagnosing active viral infections and should be used for anyone who has symptoms or known exposure to COVID-19. These tests are renowned for high sensitivity and high specificity.

(CLIA) The Clinical Laboratory Improvement Amendments regulate laboratory testing and require clinical laboratories to be certified by the Center for Medicare and Medicaid Services (CMS) before they can accept human samples for diagnostic testing.

USA COVID-19 Data as at September 9, 2020
TOTAL CASES: 6,310,663
TOTAL DEATHS: 189,147
CASES IN LAST 7 DAYS: 262,971

ARIZONA as at September 9, 2020
CONFIRMED CASES: 204,239
PROBABLE CASES: 1,806
TOTAL CASES: 206,045
CASES IN LAST 7 DAYS: 3,703
CASES/100K: 2,873
DEATHS/100K: 72

TEXAS as at September 9, 2020
TOTAL CASES: 641,791
CASES IN LAST 7 DAYS: 24,458
CASES/100K: 2,236
DEATHS/100K: 47

ABOUT EMPOWER

Empower is a vertically integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative.

ABOUT Kai Medical Laboratory

Kai Medical Laboratory is a high-complexity CLIA and COLA accredited Laboratory that provides reliable and accurate testing solutions to hospitals, medical clinics, pharmacies, and employer groups. Kai Medical Laboratory offers a wide array of testing services ranging from hematology to hormone testing, endocrinology, toxicology, and immunology. These tests are done under the supervision of its well-qualified and highly experienced scientists, medical professionals, and pharmacists. https://www.kaimedicallaboratory.com

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Dustin Klein
Director
[email protected]
720-352-1398

Investors: Steven McAuley
CEO
[email protected]
604-789-2146

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the proposed acquisition of Sun Valley; the proposed transaction terms; the expected number of clinics and patients following the closing; the future potential success of Sun Valley’s franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

Tags: , , , , , , , , , ,
Posted in Empower Clinics Inc., Featured | Comments Off on Empower Clinics $CBDT.ca Expands COVID-19 Testing Programs by Commencing RT-PCR Testing $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

July #Cannabis Sales Surge in 5 Western States – SPONSOR: Hollister Biosciences $HOLL.ca $WEED.ca $CGC $ACB $APHA $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 5:08 PM on Tuesday, September 8th, 2020

SPONSOR: Hollister Biosciences Inc. (HOLL:CSE) A vertically integrated Cannabis company with products in 230 California dispensaries, over 80 dispensaries throughout Arizona, joint ventures, licensing agreements and partnerships with Global brands. Revenue generated for the three-month period ended June 30th, 2020 was USD $8.47 million. Learn More

July Cannabis Sales Surge in 5 Western States

  • In July 2020, cannabis sales for state licensed retailers and delivery services reached $334.4 million, growing 15 percent from the trailing month and 26 percent compared to July 2019.
  • Year to date, sales in California have reached $1.9 billion, a 14 percent increase compared to the same period in 2019.
A Detailed Look at Cannabis Sales in California, Oregon, Arizona, Colorado and Nevada

Data provided by BDSA indicates that cannabis sales continued their robust expansion in 5 Western states. During July, the eleventh month after the onset of the vaping crisis and the fifth month of the pandemic impacting the market, sales across the five markets totaled $842.8 million, up 12% from June, which sequential increases of 2% in May and 14% in April. March had spiked to $666.0 million from $579.9 million in February as customers purchased cannabis ahead of store closures and concerns about limitations on access, so clearly cannabis sales are back on track. With the near-term effects of the pandemic now behind us, it’s clear that cannabis demand is surging, even in relatively mature markets, like Oregon and Colorado. Nevada continued to recover as tourism slowly returns, with sales growing 23%. California stood out with 15% sequential growth, while Colorado expanded 13%. Oregon sales climbed 6% and Arizona by 3%, but both of these states had meteoric growth from a year ago. July had one more day than June, which has the effect of adding 3% roughly.

Overall sales growth from a year ago among the five Western markets ranged from 26% in California to as high as 54% in Arizona. Nevada has been impacted by the tourist slowdown but still grew 37% from a year ago. Oregon continued its strong growth, rising 44%, while Colorado grew 35%. Concentrates represented 22-37% of sales by market, below the 26-38% share of sales last August before the vaping crisis hit.

Here is a closer look at each market, as detailed by BDSA:

Arizona

In July 2020, cannabis sales in Arizona’s medical dispensaries reached $94.2 million, growing three percent from June and over 54 percent compared to the previous July. Year-to-date through July, sales have reached $589.2 million, increasing by $194.5 million and 49 percent compared to the same period last year.

Flower sales accounted for nearly 48 percent of overall revenue for the month with $44.8 million in sales, growing one percent from June. Pre-rolled Joints, which are tracked as a separate category, accounted for just under four percent of revenue with $3.5 million in sales. Compared to the previous July, Flower sales increased by 52 percent and Pre-rolled Joints increased by 83 percent.

Concentrate sales accounted for about 37 percent of overall revenues with sales totaling $34.6 million in July, increasing six percent from the trailing month. Vape products, the largest segment of the Concentrates category, generated $21.8 million in sales, accounting for 63 percent of the Arizona Concentrates market and over 23 percent of sales across all categories. Compared to July 2019, sales of Dabbable Concentrates grew by 92 percent, while Vape sales grew by 46 percent.

The Ingestibles category accounted for nearly 11 percent of sales in July with $10 million in revenue for the month. Compared to July 2019 and June 2020, sales in the category grew by 47 percent and by four percent, respectively. In July, the $9.3 million in sales from Edibles generated nearly 93 percent of Ingestibles sales overall, while Sublinguals made up the remaining seven percent. Compared to the previous July, Edibles sales increased by 59 percent and Sublingual sales decreased by 30 percent.

California

BDSA sales reporting for the month of July reflects the state market of 699 licensed dispensary locations and 306 delivery operators.

In July 2020, cannabis sales for state licensed retailers and delivery services reached $334.4 million, growing 15 percent from the trailing month and 26 percent compared to July 2019. Year to date, sales in California have reached $1.9 billion, a 14 percent increase compared to the same period in 2019.

Sales from Flower generated $136.2 million in July 2020, accounting for nearly 41 percent of overall revenues. Compared to the trailing month and July 2019, Flower sales grew by 17 percent and 53 percent, respectively. Pre-rolled Joints, which are tracked as a separate category, accounted for nearly 11 percent of overall July revenues, with $35.6 million in sales.

Concentrates were the second-largest revenue category in July 2020, reaching $101 million in sales and accounting for over 30 percent of total revenue. Compared to the trailing month and July 2019, sales increased by 13 percent and by four percent, respectively. The $76 million in Vape sales accounted for over 75 percent of the Concentrates category and 23 percent of the month’s overall sales revenue.

In July 2020, Ingestibles generated $50.8 million in sales, increasing by 11 percent from the trailing month. Compared to July 2019, sales of Ingestibles grew by nearly 21 percent. Edibles contributed 86 percent of Ingestibles revenue, while Sublinguals made up the remaining 14 percent. Compared to July 2019, the Edibles and Sublinguals categories grew by 32 percent and declined by 22 percent, respectively.

Colorado

July 2020 was another milestone for the Colorado cannabis market. Sales in Colorado’s adult-use and medical dispensaries reached a combined $226.8 million, growing 13 percent from June. Compared to the previous July, sales increased by nearly 35 percent. Adult-use sales grew by 33 percent from July 2019 while medical sales grew by 41 percent. Year-to-date through July, combined channel sales have reached over $1.2 billion, increasing 22 percent from the same period last year.

In July, Flower sales accounted for over 47 percent of total monthly revenues, totaling at $107.2 million. Flower sales increased nearly 11 percent from the trailing month and grew 56 percent from the previous July. Year-to-date sales have increased by 40 percent in the category over the same period last year. Pre-rolled Joints, which are tracked separately from Flower, generated $13.2 million in sales for July 2020, growing 31 percent from July 2019 and increasing 17 percent from the trailing month.

The $66.5 million in Concentrate sales during July 2020 represented an 18 percent increase from the previous year and 15 percent growth from the trailing month. The category accounted for over 29 percent of revenue for the month. Vape products, the largest segment within the Concentrates category, reached $32.9 million in July sales, increasing 19 percent compared to June and four percent from the previous July, respectively. The Vape category accounted almost 50 percent of Concentrates’ revenue and 15 percent of overall sales for the month.

In July 2020, sales from Ingestibles generated $34.7 million, a 27 percent increase from July 2019. Compared to the trailing month, sales in the category grew by 17 percent. Edibles generated $32.7 million in monthly sales revenue, contributing over 94 percent to category sales and 14 percent of total revenue for the month. Sublinguals made up the remaining six percent of Ingestibles sales, totaling $1.9 million for the month.

Nevada

In July, Nevada dispensaries generated $82 million in sales. Compared to July of 2019, sales grew by 37 percent and by nearly 23 percent compared to the trailing month. Year-to-date through July, sales have reached $421.9 million, growing by six percent compared to the same period last year.

Flower sales accounted for nearly 54 percent of overall July 2020 sales. Sales in the category reached $44.1 million for the month, growing 27 percent from June. Pre-rolled Joints, tracked separately from Flower, accounted for nearly 11 percent of July sales, with $8.8 million in revenue. Compared to July 2019, Flower and Pre-rolled Joints sales have increased by 75 percent and by two percent, respectively.

Concentrate sales in July reached $18.3 million, accounting for more than 22 percent of overall revenue for the month. Compared to the trailing month as well as to the previous July, category sales increased by 17 percent. Vape products, the largest segment in the Concentrates category, generated $13.3 million for the month, contributing nearly 73 percent to Concentrates revenue and over 16 percent to total monthly sales.

Sales in the Ingestibles category accounted for 11 percent of all revenues, totaling $9.1 million in July sales and growing by about seven percent from the previous year. Compared to June, category sales grew by 17 percent. Edibles made up 90 percent of the Ingestibles category, reaching $8.2 million in July revenue, and Sublingual sales contributed the remaining ten percent.

Oregon

In July 2020, cannabis sales in Oregon’s medical and adult-use dispensaries reached a combined $106 million. Compared to the trailing month, sales in the Oregon market grew by about six percent, while compared to July 2019, sales grew by 45 percent overall. Year-to-date sales in Oregon have reached $620.3 million, growing by 39 percent compared to the same period in 2019.

Sales of Flower generated $50.3 million in July 2020, accounting for 47 percent of overall revenues. Compared to the trailing month, Flower sales grew by four percent, and compared to July 2019, sales increased by 65 percent. Pre-rolled Joints, which are tracked as a separate category, accounted for nine percent of overall revenues with $9.8 million in sales.

Concentrates generated $27.7 million in July sales. Compared to the trailing month and July 2019, sales in the category increased five percent and just over 25 percent, respectively. Vape products, the largest segment in the Concentrates category, generated $15 million in July, contributing over 54 percent of Concentrates sales and more than 14 percent of total monthly revenue.

In July 2020, Ingestibles generated over $14.6 million in sales, a nine percent increase from the previous month and nearly 25 percent compared to July 2019. Edibles, which made up 83 percent of the Ingestibles category and more than 11 percent of overall monthly sales, generated $12 million in July 2020.

For readers looking for a deeper look at cannabis markets across these five states and more, including segmentation by additional product categories, brand and item detail, longer history, and segmentation by product attributes, learn how the BDSA GreenEdge Platform can provide you with unlimited access to the most accurate and actionable data and analysis.

Source: https://www.newcannabisventures.com/july-cannabis-sales-surge-in-5-western-states/

Tags: , , , , , , , ,
Posted in Featured, Hollister Biosciences | Comments Off on July #Cannabis Sales Surge in 5 Western States – SPONSOR: Hollister Biosciences $HOLL.ca $WEED.ca $CGC $ACB $APHA $CRON.ca $OGI.ca $FAF.ca

Avicanna $AVCN.ca August 2020 Recap $KHRN.ca $TRUL.ca $VFF.ca

Posted by AGORACOM-JC at 12:04 PM on Tuesday, September 8th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

AVICANNA AUGUST 2020 RECAP

Achievements and Announcements 
August has been another incredibly progressive month for the Avicanna team with major commercial milestones being achieved. This included the nation-wide launch of our leading medical cannabis brand RHO Phyto in partnership with Medical Cannabis by Shoppers Drug Mart in Canada, the closing of a private placement financing, export of rare cannabinoids including CBG into the Unites States and strategic partnership with Red White and Bloom to distribute Pura H&W in the United States. 

See below highlights and press releases:
 
August 24, 2020

Avicanna Advances its Supply Chain Business with Commercial Exports of CBG And CBD into the United States and Germany as well as Industrial Scale THC Quota Granted by the Colombian Authorities

Avicanna majority owned subsidiary, Santa Marta Golden Hemp S.A.S. (“SMGH“) completed exports of CBG and CBD isolates into the United States, CBD isolate into Germany and the commencement of a pilot tracking system for the export of its active pharmaceutical ingredient (“API“) products in partnership with TruTrace Technologies Inc. (“TruTrace“) (CSE: TTT) (OTCQB: TTTSF). The export and sale of the commercial lot of isolated CBG into the United States was completed in parallel with commercial export of isolated CBD into the United States, as well as a pilot export for R&D purposes of CBD into Germany.  The Colombian Ministry of Justice and Law granted SMGH a supplementary cultivation quota to cultivate 12,264 psychoactive cannabis plants. 11,587 plants will be destined to produce dry flower which will then be used to manufacture psychoactive derivatives for commercial production for export. The remaining 677 plants will be utilized for psychoactive derivatives for the purposes of research and development and pilot production of our RHO Phyto™ branded products in Colombia.
 
News Release
 
August 18, 2020

Avicanna Closes Non-Brokered Private Placement Raising $2.7 Million

Avicanna closed a non-brokered private placement (the “Offering“). Under the Offering, Avicanna issued an aggregate of 1,952,410 units (the “Units“) at a price of CAD$1.40 per Unit for aggregate gross proceeds of approximately CAD$2.7 million. Avicanna intends to use the proceeds from the Offering for corporate development and general working capital purposes.
News Release
 
August 17, 2020
 
Avicanna Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Successfully launched advanced “medical cannabis 2.0” products under RHO Phyto™ brand nation-wide in Canada through Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart Revenue increase of 172% from $260,903 in Q1 2020 to $709,468 in Q2 2020, and a substantial increase from $16,571 in Q2 2019, coupled with 8% cost reduction from Q1 2020, and 31% cost reduction from Q2 2019 Continued to fortify cannabinoid research and clinical leadership position in Canada with advancements with several collaborations with world class institutions including the MC-RWE by UHN
News Release
 
August 12, 2020

Avicanna’s RHO Phyto™ Medical Product Line is Now Available Nation-Wide in Canada Through Medical Cannabis by Shoppers Inc.

RHO Phyto “Micro Drop” oil formulations are the first of the RHO Phyto formulary of advanced medical cannabis products available for patients and health care practitioners on the Medical Cannabis by Shoppers™ platform. This product line includes advanced formulations under the “Cannabis 2.0” regulations that have undergone years of research and development and been manufactured under GMP standards at MediPharm Labs Inc. The RHO Phyto products are also now available to clinicians and patients at the University Health Network through the Medical Cannabis Real World Evidence study in partnership with Medical Cannabis by Shoppers.
News Release
 
August 11, 2020

Avicanna and Red White & Bloom enter Exclusive Partnership for the Distribution and Commercialization of Pura H&W Hemp-Derived CBD-Based Topical Products in the United States

Avicanna entered into a distribution agreement for the exclusive distribution of our advanced and clinically backed CBD-based cosmetic and topical products Pura H&W™ by Red White Bloom (“RWB”) in the US and certain other markets. The launch of this innovative and premium hemp-derived CBD product line will leverage from the growing use of online platforms for shopping including Pura H&W’s own e-commerce platform, third party e-commerce channels, and “big box” retailers in addition to the existing commercial infrastructure of RWB in the United States.
News Release
 
IN CASE YOU MISSED THIS
 
August 7, 2020

Avicanna Inc. to Host Second Quarter 2020 Investor Conference Call Avicanna announced its first ever second quarter 2020 investor conference call on August 17, 2020. 

Q2 2020 Earnings Call Transcript

Tags: , , , , , , ,
Posted in All Recent Posts, Avicanna Inc., Featured | Comments Off on Avicanna $AVCN.ca August 2020 Recap $KHRN.ca $TRUL.ca $VFF.ca

Thoughtful Brands $TBI.ca Launches European Expansion Through Fully Funded Joint Venture with Franchise Cannabis $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $SHRM.ca $RVV.ca $NOVA.ca

Posted by AGORACOM at 9:01 AM on Tuesday, September 8th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/Throught_brands_logo.png
  • Formed a joint venture with Franchise Cannabis Corp. to sell and market Franchise-manufactured CBD, hemp and cosmetic products in the European Union, Switzerland, Norway and the United Kingdom

VANCOUVER, BC / ACCESSWIRE / September 8, 2020 / Thoughtful Brands Inc. (CSE:TBI FWB: 1WZ1; OTCQB: PEMTF) (the “Company” or “Thoughtful Brands“), a global natural health products and eCommerce technology company, is pleased to announce the formation of its joint venture with Franchise Cannabis Corp. (“Franchise“) to sell and market Franchise-manufactured CBD, hemp and cosmetic products in the European Union, Switzerland, Norway and the United Kingdom (the “JV Territory“).

The parties’ will share equal ownership in the joint venture. Franchise will manage procurement and fulfillment of customer orders from its European manufacturing facilities. Thoughtful Brands will provide marketing and eCommerce operations infrastructure in the JV Territory.

Franchise is a leading European-focused cannabis and pharmaceutical distribution company based in Germany with two Good Distribution Practices (GDP) certified distribution facilities, exporting to over 18 countries and currently serving a network of over 1,500 pharmacies within Germany for medical cannabis sales.

“The Thoughtful Brands agreement with Franchise ensures we are in a strong position to continue our European expansion,” said Thoughtful Brands CEO Ryan Dean Hoggan. “Our marketing expertise coupled with Franchise’s procurement and distribution facilities will allow us to grow our customer base and generate significant sales with good margins. This joint venture also enables Thoughtful Brands to duplicate the model that has made us so successful in the United States.”

Pursuant to the Transaction Agreement, Franchise has agreed to make a $500,000 equity investment into the Company through a private placement subscription of $0.20 units (the “Units“). Each Unit will consist of one (1) common share of Thoughtful Brands (each, a “Share“) and one (1) Share purchase warrant (each, a “Warrant“), with each Warrant entitling the holder to purchase one additional Share (each, a “Warrant Share“) at a price of $0.28 per Warrant Share for a period of twenty-four (24) months from their date of issue. Thoughtful Brands will then make a $350,000 equity investment into the joint venture, which will be used to develop business operations, including the initial funds to launch Franchise products in Europe using the Company’s advanced eCommerce capabilities. The Units will be subject to a four-month-and-one-day statutory hold period in accordance with applicable securities laws.

About Thoughtful Brands Inc.

Thoughtful Brands Inc. is an eCommerce technology company that researches, develops, markets, and distributes natural health products through various brands in North America and Europe. Through continuous strategic acquisitions, the Company has a strong footprint in the CBD market, as well as the burgeoning psychedelic medicine sector. Thoughtful Brands owns and operates a 110,000 square foot pharmaceutical manufacturing facility in Radebeul, Germany, where its highly skilled team conducts clinical studies utilizing naturally occurring psilocybin and other compounds found in psychedelics for the treatment of opiate addiction, while planning for future opportunities to create proprietary psilocybin products.

ON BEHALF OF THE BOARD OF DIRECTORS

THOUGHTFUL BRANDS INC.
Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected]

Tags: , , , , , ,
Posted in All Recent Posts, Thoughtful Brands Inc. | Comments Off on Thoughtful Brands $TBI.ca Launches European Expansion Through Fully Funded Joint Venture with Franchise Cannabis $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $SHRM.ca $RVV.ca $NOVA.ca

InnoCan $INNO.ca developing revolutionary products that harness the unique properties of #Cannabinoids combined with smart delivery formulations $GWPH $CRDL.ca $PCLO.ca

Posted by AGORACOM-JC at 8:23 AM on Tuesday, September 8th, 2020
Innocan-Blog

Iris Bincovich, CEO of InnoCan Pharma Corp, shares with Cannabis Report World an overview on how they are disrupting the cannabis world through pharmaceutical innovation and gives us a preview of some of their latest projects one of which is targeting the COVID-19 virus.

Can you introduce us to InnoCan? Where did the idea for the concept originate from?

InnoCan Pharma Corporation is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (“CBD”) with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals.

The founders and officers of InnoCan, all have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

InnoCan Pharma was established by Yoram Drucker, an Israeli serial entrepreneur with experience of founding companies in the field of stem cells; Ron Mayron Former CEO of Teva Israel. Teva Pharmaceutical is one of the largest generic drug producers in the world; Nir Avram, our topicals formulator, who was on the pharmaceutical innovation team at Perrigo, he holds a number of patents and has more than 30 years of experience developing topicals; and I bringing a world-wide experience in healthcare with nearly 20 years of international marketing, business development and sales experience. I have led and managed hundreds of successful international transactions in the OTC, cosmetics and dermatology sector.

InnoCan was established as a Pharma company, to enhance the therapeutic properties of CBD, developing unique synergistic delivery systems and OTC/cosmetic products.

Some of our latest projects and products: InnoCan with the Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both Central Nervous System (CNS) indications and the Covid-19 Corona Virus using CBD-loaded Exosomes.

CBD-loaded Exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

In addition, InnoCan Pharma signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection.

Together with Professor Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University, we plan to test the liposome platform on several potential indications.

InnoCan Pharma also develops and manufactures OTC products: R&G Relief & Go – a breakthrough patent-pending CBD pain relief brand, integrating CBD with other pharmaceutical ingredients.

InnoCan’s Pain relief spray provides fast action muscle relaxant and pain relief. It contains an analgesic blend of active ingredients with pure CBD to provide temporary relief of muscle and joint pain.

We also developed a line of Premium derma cosmetic CBD-integrated anti-aging product lines: SHIR, where its formulations feature a tailored blend of active ingredients and technology.

Can you tell us more about your innovative products?

1) Our latest project is a collaboration targeting the COVID-19 virus with Tel Aviv University and Professor Daniel Offen, who heads The Laboratory for Neurosciences at the Felsenstein Medical Research Center.

We are developing an inhalable treatment based on exosomes loaded with CBD, designed to target COVID-19 infected lung cells and might be applicable also to central nervous system diseases.

Exosomes have the ability to target damaged cells like a targeted missile, they improve regeneration and assist in their recovery. CBD is a known anti-inflammatory substance.

Exosomes have been studied for their cell recovery actions and inflammation targeting.  CBD-loaded exosomes (“CLX”) may hold the potential to provide anti-inflammatory properties and assist in the recovery of infected lung cells. The CBD loaded exosomes are expected to be administered by inhalation.

Together with Professor Offen, an experienced researcher on cell and gene therapy in neurodegenerative diseases, we are looking to develop a new technology that might be applicable to several indications. Prof. Offen is a co-founder of several biotechnology companies developing therapies for neurological disorders. One of them, Brainstorm Cell Therapeutics (traded on NASDQ, symbol BCLI), developed cell treatment for ALS patients, and is now in Phase III clinical trial.

2) In addition, we are advancing a platform for injectable CBD loaded liposomes in collaboration with Prof. Barenholz Head of the Laboratory of Membrane and Liposome Research of the Hebrew University – Jerusalem. This accurate, controlled administration of CBD by injection, is expected to be as easy as injecting insulin.

Upon every administration of CBD Oil, about 80% of the CBD is being throwed of by enzymes in the liver.  CBD Oil is not easily absorbed, only 5-10 % is ultimately being absorbed.  Patients may be overloaded to achieve a therapeutic level.

CBD is an oily molecule that normally cannot be easily injected into the body.  But once isolated inside a capsule, such as a Liposome, it could be injected.  Liposomes are small vesicles, that could entrap substance inside. The Liposomes technology is planned to enable increase bioavailability and control dosage and provide controlled release of CBD over time.

We are developing a platform for several potential indications.

For example, for people who are suffering from chronic pain, we may be able to offer an injection once a week, and over time, one could have a consistent release of CBD into the body.

Professor Barenholz has already developed a Liposome based breast cancer drug, named Doxil, that was licensed by Johnson & Johnson based on royalties from revenues.

InnoCan Pharma is collaborating with leading researchers’ leader in their fields.

This is one of few value-driven propositions of the company.

3) Innocan Pharma™ leverages extensive knowledge and understanding of the synergistic combination of CBD and FDA-Approved active ingredients for fast-acting relief of severe and acute pain.

R&G is a fast action muscle relaxant and pain relief brand and contains an analgesic blend of active ingredients with CBD. The brand provides temporary relief of muscle and joint pain.

These are EU-GMP manufactured products, clinically tested for safety

This PATENT PENDING UNIQUE FORMULATION combines the known benefits of CBD, Magnesium, Camphor and Menthol to relieve pain, help relax and recover after performing like professionals.

Combining these 4 ingredients at high concentrations, and developing a stable product is highly challenging.  So how does it work? Here is some science:

  • CBD- CBD is a potent antioxidant with anti-inflammatory properties. CBD is known to have a positive effect on pain and reduce swelling.
  • Menthol–a topical analgesic (pain reliever). Menthol produces a cooling sensation by stimulating the skin’s thermos-receptors, which send the brain a signal that is interpreted as cold, numbing effect.
  • Magnesiumchloride – is a known muscle relaxant and food supplement. We developed it into an easy-to-absorb form that may be able to raise levels of this nutrient within the body when applied topically to the skin.
    • The magnesium, absorbed through the skin, is claimed to relieve muscle pains and aches and to enhance relaxation.
  • Camphor- Assists to relieve pain and swelling and inflammation, and preventing skin redness.

4) Dermo cosmetic products powered by science, inspired by nature. SHIR, our beauty & science skincare brand combines the benefits of CBD with the most effective ingredients in innovative formulas to deliver visible fast acting results.

InnoCan Pharma has developed several premium lines of derma cosmetic products containing a tailor blend of highly concentrated ingredients, formulated with CBD. Each ingredient was carefully chosen to provide a synergistic effect, working in harmony with each other.

Can you describe the consumer’s behaviour towards cannabis – integrated pharmaceuticals?

As far as we know consumers are waiting to integrate Innocan Pharma’s innovation into their routine.

What challenges have you faced so far in the cannabis market and how were these overcome?

InnoCan Pharma disrupts the Cannabis world. As a pharmaceutical company, we do not grow nor extract, we focus on research and development of drug delivery platforms combining pure cannabidiol with Synergistics delivery systems of ingredients. Our challenge was to distinguish ourselves as a pharma company with highest quality standards to provide consumer confidence.

What so you see happening over the next few years regarding pharma products? What is your general prediction for the sector?

As a pharmaceutical company we predict that the Cannabis industry will move towards a much more regulated industry. Our prediction is that we will see more companies offering variety of products that combine cannabinoids among their ingredients.

What are the plans for the future and your ultimate goal?

To become a Global Leader in Cannabinoid-Integrated Pharmaceutical Products and to Improve the quality of life.

Source: https://cannabisreportworld.com/innocan-developing-revolutionary-products-that-harness-the-unique-properties-of-cannabinoids-combined-with-smart-delivery-formulations/

Tags: , , , , ,
Posted in Featured, Innocan Pharma Corporation | Comments Off on InnoCan $INNO.ca developing revolutionary products that harness the unique properties of #Cannabinoids combined with smart delivery formulations $GWPH $CRDL.ca $PCLO.ca

Thoughtful Brands Inc. $TBI.ca Announces Q2 2020 Highlights $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $SHRM.ca $RVV.ca $NOVA.ca

Posted by AGORACOM at 9:05 AM on Friday, September 4th, 2020
  • An eCommerce company specializing in natural health products chronicles latest revenue, strategic acquisitions and partnerships, expansion and trajectory
  • During a period of three months that ended June 30, 2020, the Company recorded revenue of $12,842,934

VANCOUVER, BC / ACCESSWIRE / September 4, 2020 / Global natural health products and eCommerce technology company Thoughtful Brands Inc. (CSE:TBI)(FSE:1WZ1)(OTCQB:PEMTF) (the “Company” or “Thoughtful Brands“), which recently changed its name from Mota Ventures Corp. to better reflect the Company’s long-term growth strategy, is proud to announce its second quarter 2020 earnings results, as reported on August 31, 2020.

During a period of three months that ended June 30, 2020, the Company recorded revenue of $12,842,934, which was primarily due to the operations and strong sales performances of the Nature’s Exclusive CBD brand, whose product line led to a major sales boost amid the COVID-19 pandemic. Cost of goods sold amounted to $11,293,727 during the three months ended June 30, 2020. Cost of goods sold included costs for product fulfillment, as well as eCommerce campaign costs including customer acquisition. Revenues grew by 68% in the second quarter. Customers acquired for the twelve months ended June 30, 2020 reached 202,564 up from 44,207 compared with the twelve months ended June 30, 2019. Gross margin in Q2 2020 increased to 12%, as compared to gross margin in Q1 2020 of 8%, due to increased efficiencies in operations and increased customer acquisition due to online marketing campaigns in the current period.

“The Thoughtful Brands team would like to emphasize the Company’s commitment to its partners, the integral role of supply chain across its businesses, and its unrelenting effort to provide the best possible experience for its customers,” said CEO Ryan Hoggan. “Each of the ventures outlined below is part of our broader expansion plan and we’re looking forward to the remainder of 2020 and beyond.”

Key Highlights for the six months ended June 30, 2020

Financing

In April 2020, the Company completed a non-brokered private placement for gross proceeds of $4.5 million.

Acquisitions & Joint Ventures

On June 1, 2020 the Company completed its acquisition of Verrian, which owns and operates a 110,000 square foot pharmaceutical manufacturing facility in Radebuel, Germany. Operations within this full suite pharmaceutical manufacturing site include analytical laboratory and finished dose manufacturing, which exceed all international quality standards. The facility and equipment of Verrian have been independently appraised at Cdn$10,600,000 and include an analytical laboratory and full pharmaceutical manufacturing suite. Verrian also specializes in the development of psychedelic-derived medicines with the goal of formulating treatments for addictions-including opioids and alcohol. The move propelled Thoughtful Brands into the burgeoning psychedelic market and supports the Company’s forays into the natural health sector beyond the cannabidiol (“CBD“) market.

On April 7, 2020 the Company acquired a 20% ownership interest in Folium Life Sciences Inc., a Health Canada-licensed cannabis cultivator. Folium is expanding its licensed indoor cannabis production facility on Vancouver Island to produce a high quality and consistent cannabis product on site.

On March 25, 2020 the Company, through its Spanish subsidiary Global Zifar S.L., acquired the intellectual property and trade names of “Sativida” in Spain, and will license both back to Sativida in exchange for a royalty associated with the gross revenues generated by Sativida. Sativida is a producer and online retailer of CBD and branded CBD products in certain jurisdictions in Europe, including Spain, Portugal, Austria, Germany, France and the UK. Sativida is also the top search-ranked online retailer of CBD products in Spain and Mexico and plans to continue expanding its footprint in Europe and Latin America.

On January 17, 2020 Thoughtful Brands completed its acquisition of First Class CBD (which was re-branded as Nature’s Exclusive on April 6, 2020), an online direct-to-consumer retail distributor in the United States. Nature’s Exclusive offers a CBD hemp-oil formula intended to provide users with the therapeutic benefits that hemp-derived CBD may offer. The hemp oil used in the products is derived from hemp grown and cultivated in the United States. The extraction process is designed to maintain all the beneficial qualities that hemp may offer. Natures Exclusive offers a range of products, which include CBD oil drops, CBD gummies, CBD pain relief cream and CBD skin serum.

In January 2020, the Company’s wholly-owned subsidiary Ihuana S.A.S entered into a research cooperation agreement with La Fundacion Universitaria de Ciencias de la Salud (The University Foundation of Health Sciences) located in Bogota, Colombia. Pursuant to the agreement with the university, the parties agreed to engage in research and formulation of medicinal products made with non-psychoactive cannabis and cannabis byproducts.

In January 2020, Ihuana completed its 2,000 square foot research and development facility in Guasca, Colombia. The purpose-built R&D facility is for a seed registration program on Ihuana’s licensed land. This was a significant step, as it allows Ihuana to register the genetics of its high-CBD, low-THC strains of cannabis with the Colombian Agricultural Institute (Instituto Colombiano Agroprecuario, or ICA).

Key highlights subsequent to June 30, 2020

On August 22, 2020, the Company, through its wholly-owned US subsidiary, Ecommerce Tech LLC, acquired the rights to an eCommerce software platform from Unified Funding LLC’s wholly-owned subsidiary, Offer Space LLC. Prior to the Software acquisition, the Software was being used by the Company’s Nature’s Exclusive brand, and by the newly acquired brands, Golden Path and Wild Mariposa, through service agreements with Offer Space. The acquisition of the asset provides the Company with the opportunity to capture previously unrealized value from the products it launches in the online natural health market. The Software facilitated over Cdn$350 million in consumer transactions, including Cdn$93.8 million in 2019. The asset enhances the management of the Company’s already profitable online brands, and allows the Company to launch new products and enter into emerging natural health markets worldwide, more efficiently.

On August 19, 2020, the Company acquired Golden Path LLC and Wild Mariposa LLC, two direct-to-consumer eCommerce brands offering a range of natural health products, including nutraceutical and hemp-based CBD, within the United States. Every product manufactured is third-party tested for purity and manufactured in the United States in GMP certified facilities. The acquisitions expanded the Company’s portfolio in the nutraceutical and hemp-based CBD product space.

On July 21, 2020, the Company entered into a binding agreement with Franchise Cannabis Corp. to form a joint venture in Europe to sell and market Franchise-manufactured CBD, hemp and cosmetic products in the European Union, Switzerland, Norway and the United Kingdom. Sales of the custom-manufactured products will be sold online utilizing the Company’s eCommerce infrastructure.

Franchise is a European-focused cannabis and pharmaceutical distribution company based in Germany with two Good Distribution Practices (GDP) certified distribution facilities, exporting to over 18 countries and currently serving a network of over 1,500 pharmacies within Germany for medical cannabis sales.

About Thoughtful Brands Inc.

Thoughtful Brands Inc. is an eCommerce technology company that researches, develops, markets, and distributes natural health products through various brands in North America and Europe. Through continuous strategic acquisitions, the Company has a strong footprint in the CBD market, as well as the burgeoning psychedelic medicine sector. Thoughtful Brands owns and operates a 110,000 square foot pharmaceutical manufacturing facility in Radebeul, Germany, where its highly skilled team conducts clinical studies utilizing naturally occurring psilocybin and other compounds found in psychedelics for the treatment of opiate addiction, while planning for future opportunities to create proprietary psilocybin products.

ON BEHALF OF THE BOARD OF DIRECTORS
THOUGHTFUL BRANDS INC.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected]

Tags: , , , , ,
Posted in All Recent Posts, Thoughtful Brands Inc. | Comments Off on Thoughtful Brands Inc. $TBI.ca Announces Q2 2020 Highlights $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $SHRM.ca $RVV.ca $NOVA.ca

Avicanna $AVCN.ca $AVCNF Advances its Supply Chain Business and Announces Filing of Amended Interim Financial Statements $KHRN.ca $TRUL.ca $VFF.ca

Posted by AGORACOM-JC at 8:31 AM on Friday, September 4th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg
  • Company has completed exports of CBD water soluble formula into the United States and CBD-based cosmetics into the United Kingdom
  • Company is also pleased to announce that the Colombian Ministry of Health has granted SMGH a commercial and industrial fabrication quota to produce psychoactive THC derivatives.
  • The export and sale of the commercial lot of isolated CBD water soluble formula into the United States was completed in parallel with an export of CBD-based cosmetics into the United Kingdom
  • The cultivation, extraction and purification of these products were all completed through Avicanna’s vertical integration at SMGH and validate the Company’s innovation and leadership in natural rare cannabinoid production

TORONTO, Sept. 4, 2020 – Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products announces that through its majority owned subsidiary, Santa Marta Golden Hemp S.A.S. (“SMGH“), the Company has completed exports of CBD water soluble formula into the United States and CBD-based cosmetics into the United Kingdom. The Company is also pleased to announce that the Colombian Ministry of Health has granted SMGH a commercial and industrial fabrication quota to produce psychoactive THC derivatives. 

The Company also announces that it has amended and refiled its interim financial statements for the period ended June 30, 2020 (the “Interim Financial Statements”) which amend the Company’s interim financial statements for the same period originally filed on SEDAR on August 14, 2020. At the request of the Ontario Securities Commission, the Interim Financial Statements have been updated to include comparative financial information for the corresponding interim period in the immediately preceding financial year as such information was inadvertently omitted in the initial filing. The changes are for presentation purposes and no figures have been restated. The Company has updated the Statement of Changes in Equity to include the immediately preceding financial year June 30, 2019 balances as required by Section 4.3(2)(b) of National Instrument 51-102 – Continuous Disclosure Obligations.

The export and sale of the commercial lot of isolated CBD water soluble formula into the United States was completed in parallel with an export of CBD-based cosmetics into the United Kingdom. The cultivation, extraction and purification of these products were all completed through Avicanna’s vertical integration at SMGH and validate the Company’s innovation and leadership in natural rare cannabinoid production. The CBD water soluble formula is part of the Aureus™ product portfolio that now includes feminized seeds and advanced formulations as well as CBD, CBG and THC API products. The CBD-based cosmetics were manufactured using CBD produced by SMGH and formulas developed by Avicanna.

The Colombian Ministry of Health granted SMGH a supplementary fabrication quota to receive 1.4 tons of dry flower and transform them into approximately 150 kg of psychoactive derivatives which will be used for commercial exports.

To the knowledge of the Company, it carries out its operations in compliance with all applicable laws in the jurisdictions in which it operates.

About Avicanna

Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments. 

Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna’s team of experts have developed and commercialized several industry leading product lines, including: 

  • Pura H&W™: an advanced and clinically tested line of CBD consumer derma-cosmetic products; and, 
  • RHO Phyto™: an advanced line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced “Cannabis 2.0” products, containing oils, sprays, capsules, creams, and gels, all developed with scientific rigour, manufactured under GMP standards and supported by pre-clinical data. 

With ongoing clinical trials on its derma-cosmetic (Pura H&W), medical cannabis (RHO Phyto) and a pipeline of pharmaceutical products, Avicanna’s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company’s vision since its inception. Furthermore, Avicanna’s commitment to education is demonstrated through its annual medical symposium, the Avicanna Academy educational platform, and the My Cannabis Clinic patient program through its subsidiary company. 

Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia. Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients. Avicanna’s Avesta Genetica program specializes in the development and optimization of rare cultivars for commercial production along with feminized seeds for global export. In June 2020, Avicanna made history with a shipment of hemp seeds to the United States of America by completing the first ever export of hemp seeds from Colombia.

Stay Connected

For more information about Avicanna, visit www.avicanna.com, call 1-647-243-5283, or contact Setu Purohit, President by email at [email protected].

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and includes statements with respect to the ability of the Company to complete additional exports of  CBD water soluble formula to the United States, the ability of the Company to complete additional exports of CBD-based cosmetics in to the United Kingdom, the ability of the Company to continue manufacturing CBD-based cosmetics using CBD produced by SMGH, the ability of SMGH to receive 1.4 tons of dry flower for the purposes of extracting psychoactive derivatives, and the ability of SMGH to produce 150 kg of psychoactive derivatives. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated April 15, 2020, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com.

The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Tags: , , , , , , , ,
Posted in Avicanna Inc., Featured | Comments Off on Avicanna $AVCN.ca $AVCNF Advances its Supply Chain Business and Announces Filing of Amended Interim Financial Statements $KHRN.ca $TRUL.ca $VFF.ca

Innocan Pharma $INNO.ca Announces Publication of Enterprise Report by Mackie Research $GWPH $CRDL.ca $PCLO.ca

Posted by AGORACOM-JC at 7:17 AM on Thursday, September 3rd, 2020
Innocan-Blog

Mackie Research’s analyst, Yue (Toby) Ma, Ph.D., indicates in the updated Enterprise report that Innocan’s potential catalysts are:

  • Clinical Catalyst: Pre-clinical data of CLX in COVID-19 is expected in 9 to 12 months.
  • Licensing Catalyst: Innocan is looking to out-license CLX and the liposome product before Phase 1 trials.
  • Commercial Catalyst: Innocan’s CBD-based consumer health products are expected to be launched in several international markets in Q4 2020. The company is looking to sign more regional distribution agreements going forward.

Herzliya, Israel and Calgary, Alberta–(September 3, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan”), is pleased to announce that Mackie Research Capital Corporation’s institutional sales group has issued an updated Enterprise report on the Company.

The Enterprise report provides valuable insight into companies that embody value-add for investors, have distinguished themselves among their peers and are bringing innovative and creative ideas into action.

Mackie Research’s analyst, Yue (Toby) Ma, Ph.D., indicates in the updated Enterprise report that Innocan’s potential catalysts are:

  1. Clinical Catalyst: Pre-clinical data of CLX in COVID-19 is expected in 9 to 12 months.
  2. Licensing Catalyst: Innocan is looking to out-license CLX and the liposome product before Phase 1 trials.
  3. Commercial Catalyst: Innocan’s CBD-based consumer health products are expected to be launched in several international markets in Q4 2020. The company is looking to sign more regional distribution agreements going forward.

This Enterprise report is based upon general comments with no ratings and should not be construed to be a research report.

About Innocan

The Company, through its wholly owned subsidiary, Innocan Pharma Ltd., is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (“CBD”). Innocan and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-Loaded Exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

The Company signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem to develop a CBD drug delivery platform based on a unique-controlled release Liposome to be administrated by Injection. The Company plans, together with Prof. Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University to test the Liposome platform on several potential indications. The Company is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of InnoCan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond InnoCan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by InnoCan, including expectations and assumptions concerning the anticipated benefits of the product, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact InnoCan can also be found in InnoCan’s public reports and filings which are available under InnoCan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. InnoCan Pharma does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law. Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Tags: , , , , , ,
Posted in All Recent Posts, Featured, Innocan Pharma Corporation | Comments Off on Innocan Pharma $INNO.ca Announces Publication of Enterprise Report by Mackie Research $GWPH $CRDL.ca $PCLO.ca

VIDEO – Hollister $HOLL.ca Reports Record Q2 Revenues With $8.47M From 300+ Dispensaries In California and Arizona $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 6:28 PM on Tuesday, September 1st, 2020
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1

Hollister Biosciences (HOLL:CSE). is a multi-state operator with multiple, high-quality products that are now carried in 230 of California’s 600 dispensaries, where it also claims California’s #1 hash infused pre-roll “HashBone” + another 80 Arizona dispensaries with some of the best concentrate in the State.  

But given the state of disappointment in the Cannabis industry over the last 15 months, none of that would mean anything without actual results shareholders and the industry could celebrate.  In that regard, Hollister does not disappoint with Q2 numbers coming in as follows:

  • RECORD REVENUE of $US 8.47M, compared to $200,000 last year and representing an increase of 4,170%
  • NET INCOME of $300,000, compared to a loss of $2.1M, representing a turnaround of $2.4M over last year 

There isn’t a small cap cannabis company that would not cheer for these results – if that was all they had.  These numbers are a company maker.   But Hollister is set to continue growing on several fronts, including a Direct To Consumer model and further big expansion in California.  

Watch this incredible interview with President Alex Somjen.   

Watch this interview or listen by Podcast on Apple, Google, Spotify or your favourite podcaster.

Tags: , , , , , , , , , , , ,
Posted in AGORACOM Via Satellite, All Recent Posts, Featured, Hollister Biosciences | Comments Off on VIDEO – Hollister $HOLL.ca Reports Record Q2 Revenues With $8.47M From 300+ Dispensaries In California and Arizona $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Primo Nutraceuticals Inc. $PRMO.ca and Dan Duquette Former MLB Executive Enter into Letter of Intent for the Development of a Global Supply of #PPE products & Primo Hand Sanitizer

Posted by AGORACOM-JC at 8:50 AM on Tuesday, September 1st, 2020
  • Entered into a Letter of Intent with Duquette Consulting LLC (the “LOI”), a company owned by Dan Duquette.
  • Dan Duquette is a twice named Major League Baseball (MLB) Executive of the Year and former Executive Vice-President of the Baltimore Orioles, General Manager of the Montreal Expos, Boston Red Sox, and Milwaukee Brewers
  • Dan Duquette has joined forces with Primo Nutraceuticals to partner in the development, sourcing and the global supply of personal protective equipment products including Primo’s hand sanitizer

VANCOUVER, British Columbia, Sept. 01, 2020 — PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVD) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (“Primo” or the “Company”) is pleased to announce it has entered into a Letter of Intent with Duquette Consulting LLC (the “LOI”), a company owned by Dan Duquette. Dan Duquette is a twice named Major League Baseball (MLB) Executive of the Year and former Executive Vice-President of the Baltimore Orioles, General Manager of the Montreal Expos, Boston Red Sox, and Milwaukee Brewers (https://en.wikipedia.org/wiki/Dan_Duquette). Dan Duquette has joined forces with Primo Nutraceuticals to partner in the development, sourcing and the global supply of personal protective equipment (“PPE”) products including Primo’s hand sanitizer.

In June 2020 Primo received its first shipment of its lemon hand sanitizer and immediately began sending out samples to procurement departments, receiving positive feedback regarding the quality of the product. Duquette Consulting & their affiliates will help Primo in marketing the hand sanitizer via their partnership channels, marketing brochures & e-commerce sites exposing the Company’s products on a global scale. As Primo is expanding into the Canadian market the Company must have an MDEL (Medical Device Establishment License) to comply with the regulations of Health Canada relating to companies seeking to sell, distribute, manufacture or import medical equipment in Canada. Primo and Duquette Consulting will work towards securing the necessary licenses required to sell nitrile gloves, N95 surgical masks & KN95 masks and gowns. The Company is extremely focused on developing the right partnerships that will encourage the Company’s growth into the market sector of health and wellness. Primo is extremely optimistic that building these strategic types of relationships will prove fruitful for the Company and its shareholders in the very near future.

Duquette Consulting entered the PPE market by sourcing and selling products and supplies at a government & state level to help in the fight against COVID-19, securing, shipping and recently delivering over 5 million masks to the State of Maryland in the United States (the “U.S”). Duquette Consulting partnered with Crowley Worldwide (www.crowley.com) a large logistics conglomerate with over USD $2 billion in annual revenue, offering services to the U.S. Department of Defense, the Department of Homeland Security and other state and federal agencies in the U.S.; top medical equipment suppliers, with financial backing by Citibank. A Duquette Consulting press release is located at the following link: https://dcppe.net/case-study/

The strategic partnership contemplated in the LOI is extremely beneficial for Primo, opening the doors to potential massive orders for the Company’s hand sanitizer worldwide. With the recent issuance of a Government Procurement number to Primo by the Canada Revenue Agency and the LOI with Duquette Consulting LLC, Primo could soon be able to bid on government tenders not only for hand sanitizer, but for N95 surgical masks, KN95 masks, nitrile surgical gloves and gowns. All PPE products would meet the certification standards of the market place including the FDA, CDC, MOD and NIOSH approval requirements.

Richard Cindric, CEO of Primo comments:“We are excited to partner with Mr. Duquette. Together we will provide our line of hand sanitizer to Dan’s already established PPE supply chain processes and distribution network of companies across the U.S.A. and abroad.”

Andy Jagpal, President of Primo comments: “We are extremely pleased to partner with Mr. Duquette to develop a global supply chain of personal protection equipment. We look forward to working with Dan and his team.”

Dan Duquette, CEO Duquette Consulting LLC comments: “Our new partnership with Primo contemplated in the LOI will afford Duquette Consulting the opportunity to broaden our offerings to those in need of PPE.  Our recent success in supplying the State of Maryland with over five millions NIOSH approved Surgical Masks is a prime example of our ability to meet the need of institutional buyers who are looking for both quality products from a reputable firm who can deliver in an expedient and cost effective manner. As well as adding in our ability to finance our transactions is a significant differentiator that separates us in the PPE marketplace.”

Joel DeBellefeuille, Director of Primo comments: ”I’ve known Dan for a few years now and I couldn’t be happier to continue working and collaborating with him on amazing deals and partnerships. This is a major plus for Primo and its shareholders. Dan is an extremely influential person with a network of people spanning the globe.”

About Dan Duquette

Dan Duquette is a MLB veteran (Major League Baseball) Executive whose leadership built winning teams and enterprise value of club and media assets over an 18 year career. Successfully executing plans to immediately turn around the Montreal Expos, Boston Red Sox and Baltimore Orioles as entertaining teams to grow fan base, improve revenues, expand market share and improve content distribution. He is also the founder of the Dan Duquette Sports Academy. He has twice been named the Major League Baseball Executive of the Year by Sporting News in 1992 with the Expos and in 2014 with the Baltimore Orioles.

About Duquette Consulting LLC

Duquette Consulting is a management consulting company. With the advent of the worldwide pandemic, we have focused our efforts to help combat the effects of COVID19. In doing so, we established a network of international companies and entities who specialize in supporting the emergency management community in times of crisis. As part of our covid-19 initiative, Duquette Consulting manages and coordinates the procurement and acquisition for both the public and private sectors, domestically and internationally of Personal Protection Equipment (PPE). Our partnership has banking relationships that allow Duquette Consulting’s Partnership group the ability to finance large scale supply of PPE items such as masks, gloves and gowns. Our products are of the highest quality and meet the certifications standards of the marketplace including the FDA, CDC, MOD, and NIOSH approval requirements.

About Primo Nutraceuticals

Primo Nutraceuticals Inc. (“Primo” or the “Company”) provides strategic capital to the thriving cannabis cultivation sector through ownership and development of commercial real estate and farm friendly properties. Primo is dedicated to funding the rapid growth in production, processing, retail and branding of cannabis and cannabis related products in Canada and the United States. Primo has invested in several brands and is pursuing partnerships with retailers and distribution companies in Canada and the United States. Primo’s management is in the process of building a corporate road map to further vertically integrate the Company, specifically by way of “Primo” branded retail outlets – offering “Thrive,” “Primo,” and a selection of curated partner brands. The Company possesses proprietary formulas for cannabis edibles, topical, and tinctures. Primo is focused on building a strong presence in the hemp industry with the objective of extracting and selling cannabinoids (CBD) products in both Canada and the United States.

On behalf of the Board of Directors

PRIMO NUTRACEUTICALS INC.

“Andy Jagpal”

Andy Jagpal
President and Director

For further information, please contact Zoltan, IR Representative at: 604-722-0305, or; [email protected].

To learn more about what this news means to the shareholders visit:

www.primonutraceuticals.com
www.twitter.com/Prmoinc
www.thrivecbd.com
www.mariannacorp.com
www.dcppe.net

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
No regulatory authority has approved or disapproved the information contained in this news release.

Tags: , , , , , , ,
Posted in PRIMO Nutraceuticals Inc. | Comments Off on Primo Nutraceuticals Inc. $PRMO.ca and Dan Duquette Former MLB Executive Enter into Letter of Intent for the Development of a Global Supply of #PPE products & Primo Hand Sanitizer

« Older Entries
Newer Entries »